Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata - National Alopecia Areata Foundation | NAAF

Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata

Study type: Clinical Trials Posting date: 09/17/2025 Last updated: 01/05/2026 Status: Active Phase: Phase 3 Eligibility:

Clinical presentation compatible with alopecia areata with a current episode lasting at least 6 months and not exceeding 10 years; between 12 to <18 years of age; at least 50% scalp hair loss; willing to comply with the study visits and requirements of the study protocol
Drug: deuruxolitinib (Leqselvi) Administration: oral Sponsor: Sun Pharma Sponsor Link: Click here ClinicalTrials.gov link: Click here Location: Multiple locations in USA and Canada


 Description:
This study evaluates the safety and effectiveness of deuruxolitinib (Leqselvi) in adolescents aged 12 to less than 18 years who have 50% or greater scalp hair loss, beginning with a double-blind, randomized, placebo-controlled Treatment Period of 24 weeks. Subjects 12 to <18 years of age having at least 50% hair loss as measured by SALT and meeting eligibility criteria will be randomized to deuruxolitinib or placebo treatment. In the Open-label Extension part of the study, participants from the Treatment Period will receive deuruxolitinib for 52 weeks.
For more information, visit this study link or view the trial listing on Clinicaltrials.gov.